Regeneron Pharmaceuticals, Inc. (REGN) Handily Tops Q2 EPS Views; Revs Heavy

July 25, 2012 6:34 AM EDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q2 EPS of $0.90, $0.65 better than the analyst estimate of $0.25. Revenue for the quarter came in at $304 million versus the consensus estimate of $255.98 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings